H.C. Wainwright analyst Yi Chen downgraded OpGen to Neutral from Buy without a price target following the sales miss in Q2. The company continues to consider all alternatives, which include obtaining relief under U.S. and applicable foreign bankruptcy laws, the analyst tells investors in a research note. In view of the Q2 update, the firm believes it is prudent to downgrade the shares pending further updates from the company.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on OPGN:
- OpGen Reports Second Quarter 2023 Financial Results and Provides Business Update
- OpGen’s subsidiary releases new features to its AREScloud offering
- OpGen’s Subsidiary Ares Genetics Releases New Features to its AREScloud Offering
- OpGen’s subsidiary Curetis, FIND extend R&D collaboration agreement
- OpGen to Provide Business Update and Financial Results for the Second Quarter 2023 on August 10th at 4:30 p.m. Eastern Time
